Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Breathing system

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    79 result(s) found for: Breathing system. Displaying page 1 of 4.
    1  2  3  4  Next»
    EudraCT Number: 2009-014301-14 Sponsor Protocol Number: 2009-014301-14 Start Date*: 2009-07-15
    Sponsor Name:ISTITUTO NAZIONALE PER LA CURA TUMORI
    Full Title: Farmacologic prevention with Varenicline in heavy smokers undergoing early detection lung cancer screening
    Medical condition: Heavy smokers with higher risk in developing lung cancer and smoke related diseases
    Disease: Version SOC Term Classification Code Term Level
    9.1 10038738 SOC
    9.1 10038716 HLGT
    9.1 10029107 HLGT
    9.1 10006334 HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-002342-23 Sponsor Protocol Number: 58166 Start Date*: 2016-07-29
    Sponsor Name:VU University Medical Center
    Full Title: The cardiovascular dose-response to supplemental oxygen in healthy volunteers
    Medical condition: Healthy cardiovascular system
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-019986-27 Sponsor Protocol Number: RESPIRO Start Date*: 2010-06-02
    Sponsor Name:ISTITUTO AUXOLOGICO ITALIANO
    Full Title: Breathing disorders in heart failure: high altitude hypoxia as a model to define diagnostic tools, therapeutic strategies and gender related differences.
    Medical condition: Chronic heart failure
    Disease: Version SOC Term Classification Code Term Level
    9.1 10019280 HLGT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-004448-20 Sponsor Protocol Number: Sarizotan/001/II/2015 Start Date*: 2016-11-28
    Sponsor Name:Newron Pharmaceuticals S.p.A.
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Six-Month Study to Evaluate the Efficacy, Safety and Tolerability of Sarizotan in Patients with Rett Syndrome with Respiratory Symptoms
    Medical condition: Rett syndrome
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10039000 Rett's disorder LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-004064-11 Sponsor Protocol Number: BETTER-BFeasibility Start Date*: 2016-02-16
    Sponsor Name:King's College London [...]
    1. King's College London
    2. King's College Hospital NHS Foundation Trust
    Full Title: BETTER-B (Feasibility) BETter TreatmEnts for Refractory Breathlessness: A feasibility study of the use of mirtazapine for refractory breathlessness
    Medical condition: Refractory breathlessness in patients diagnosed with cancer, chronic heart failure, or lung disease (chronic obstructive pulmonary disease (COPD) or interstitial lung disease (ILD)).
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004855 10006345 Breathlessness LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2018-001650-98 Sponsor Protocol Number: AC1802 Start Date*: 2018-12-10
    Sponsor Name:University of Edinburgh and NHS Lothian [...]
    1. University of Edinburgh and NHS Lothian
    2. NHS Lothian
    Full Title: Alpha 2 agonists for sedation to produce better outcomes from critical illness (A2B Trial): A randomised, parallel-group, allocation concealed, controlled, open, phase 3 pragmatic clinical and cost...
    Medical condition: Any patient requiring intensive care treatment due to critical illness.
    Disease: Version SOC Term Classification Code Term Level
    20.1 10029205 - Nervous system disorders 10033305 Oversedation LLT
    20.0 10029205 - Nervous system disorders 10039897 Sedation PT
    21.1 100000004865 10049124 Sedation during medical procedure LLT
    20.1 10029205 - Nervous system disorders 10039898 Sedation excessive LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2021-006427-18 Sponsor Protocol Number: 2021.143 Start Date*: 2022-08-26
    Sponsor Name:Anna Coquard Rafales
    Full Title: M-POC-O2: high flow nasal cannula oxygen versus conventional oxygen therapy in exacerbated chronic obstructive pulmonary disease (COPD) patients without respiratory acidosis. Pilot Study.
    Medical condition: Patients older than 35 years old with COPD diagnosis (chronic obstructive pulmonary disease) by spirometry, presenting acute exacerbation without respiratory acidosis.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-003666-41 Sponsor Protocol Number: MEC2020-0078 Start Date*: 2020-04-21
    Sponsor Name:Erasmus MC University Medical Center
    Full Title: Doxapram versus placebo in preterm newborns: an international double blinded multicenter randomized controlled trial.
    Medical condition: Preterm infants are at high risk of respiratory failure due to immaturity of the respiratory system. Respiratory failure is caused by a comprised lung function and impaired control of breathing. Co...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10077323 Infantile mixed apnea LLT
    Population Age: Preterm newborn infants, Under 18 Gender: Male, Female
    Trial protocol: NL (Trial now transitioned) BE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-004917-15 Sponsor Protocol Number: RebOx Start Date*: 2020-04-22
    Sponsor Name:ISTITUTO AUXOLOGICO ITALIANO
    Full Title: Crossover, Double-blind, Phase 2 Study of a Fixed Dose Combination of Reboxetine\Oxybutynin (AD128) Versus Placebo in Obstructive Sleep Apnea (RebOx)
    Medical condition: Obstructive Sleep Apnea
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004852 10040978 Sleep apnoeas HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-003424-31 Sponsor Protocol Number: I4V-MC-JAGA Start Date*: Information not available in EudraCT
    Sponsor Name:Eli Lilly and Company
    Full Title: Treatment of Conditions Expected to Benefit from JAK 1/2 Inhibition: CANDLE, CANDLE-Related Conditions, SAVI, and Severe Juvenile Dermatomyositis
    Medical condition: CANDLE, CANDLE-Related Conditions, SAVI, and Severe Juvenile Dermatomyositis, Aicardi-Goutieres Syndrome
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2021-004994-30 Sponsor Protocol Number: NL68837.091.21 Start Date*: 2022-02-08
    Sponsor Name:Roessingh
    Full Title: Pulmonary function and sleep related disorders during cervical admission of intrathecal baclofen in spinal cord injury; a safety study
    Medical condition: Spasticity in patients with spinal cord injury
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-001235-27 Sponsor Protocol Number: AVXS-101-CL-101 Start Date*: 2020-04-06
    Sponsor Name:AveXis, Inc.
    Full Title: Phase I Gene Transfer Clinical Trial for Spinal Muscular Atrophy Type 1 Delivering AVXS-101
    Medical condition: Gene Replacement Therapy Clinical Trial for Patients with Spinal Muscular Atrophy Type 1
    Disease:
    Population Age: Newborns, Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2020-002434-33 Sponsor Protocol Number: Aprotinin1.0. Start Date*: 2020-10-16
    Sponsor Name:Hospital General Universitario Ciudad Real
    Full Title: Phase 3 randomized study to evaluate the safety and efficacy of aprotinin (Trasylol®) administered by inhalation nebulization in patients diagnosed with SARS-CoV-2 (COVID-19) with moderate severity...
    Medical condition: Patients with moderate SARS-CoV-2 pneumonia confirmed with a diagnosis of polymerase chain reaction (PCR) before randomization. The patient should be hospitalized and require ongoing medical care f...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2005-004087-24 Sponsor Protocol Number: FEN-PAI-3002 Start Date*: 2008-01-29
    Sponsor Name:JANSSEN-CILAG GmbH
    Full Title: Global assessment of treatment with IONSYS and its handling by patients, doctors and nursing staff in the management of acute moderate to severe post-surgery pain in hospitalised patients.
    Medical condition: Acute, moderate to severe postoperative pain after elective surgery in a hospital setting in patients needing at least 24 hours strong opioids for pain therapy.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10054711 Postoperative pain LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2012-002862-11 Sponsor Protocol Number: CXA-NP-11-04 Start Date*: 2015-07-27
    Sponsor Name:Cubist Pharmaceuticals GmbH
    Full Title: A Prospective, Randomized, Double-Blind, Multicenter, Phase 3 Study to Assess the Safety and Efficacy of Intravenous Ceftolozane/tazobactam Compared With Meropenem in Adult Patients with Ventilated...
    Medical condition: Ventilated Nosocomial Pneumonia
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004862 10052596 Nosocomial pneumonia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) EE (Completed) DE (Completed) BE (Completed) LV (Completed) CZ (Completed) HU (Completed) SK (Completed) AT (Completed) GR (Completed) PT (Completed) HR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2010-022558-18 Sponsor Protocol Number: 2010-022558-18 Start Date*: 2010-10-11
    Sponsor Name:AZIENDA OSPEDALIERA DI PADOVA
    Full Title: A pilot trial with clenbuterol in spinal and bulbar muscular atrophy (SBMA).
    Medical condition: spinal and bulbar muscular atrophy (SBMA)
    Disease: Version SOC Term Classification Code Term Level
    15.0 10029205 - Nervous system disorders 10029317 Neuromuscular disorders HLGT
    15.0 10029205 - Nervous system disorders 10029205 Nervous system disorders SOC
    15.0 10028395 - Musculoskeletal and connective tissue disorders 10047868 Weakness of limbs LLT
    15.0 10038738 - Respiratory, thoracic and mediastinal disorders 10013969 Dyspnoea at rest PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-001953-24 Sponsor Protocol Number: WON001 Start Date*: 2007-07-21
    Sponsor Name:University of Dundee
    Full Title: ''Metformin in Insulin Resistant LV Dysfunction, a double-blind, placebo-controlled trial''
    Medical condition: Patients who has heart failure and found to be insulin resistant (pre-diabetic state). Insulin resistance can be identified using a blood test.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-000540-14 Sponsor Protocol Number: HIGHCARE Start Date*: 2008-05-20
    Sponsor Name:ISTITUTO AUXOLOGICO ITALIANO
    Full Title: Role of the renin-angiotensin system in the cardiovascular, metabolic, neurologic and respiratory response to hypobaric hypoxia during sustained exposure to high altitude.
    Medical condition: This study is aimed at the investigation of adaptative physiological mechanisms at high altitude and not at the development of new therapeutic indications.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10007541 Cardiac disorders SOC
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-000529-20 Sponsor Protocol Number: FENHYDPAI4012 Start Date*: 2008-05-20
    Sponsor Name:Janssen-Cilag Limited
    Full Title: Comparison of Ionsys® and routine care with morphine IV PCA in the management of early post-operative mobilisation, ability to mobilise and in time to Fitness For Discharge (FFD)
    Medical condition: Evaluation of the mobilisation characteristics, clinical use, safety and Ease of Care (EOC) of a Fentanyl Iontophoretic Transdermal PCA system (Ionsys) and morphine IV PCA for management of acute...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-002099-15 Sponsor Protocol Number: APOCT-001 Start Date*: 2014-09-15
    Sponsor Name:Apodemus AB
    Full Title: A randomised, double blind, placebo controlled trial to evaluate the safety and efficacy of Apovir for treatment of patients with Amyotrophic lateral sclerosis
    Medical condition: Amyotrophic Lateral Sclerosis (ALS)
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029205 - Nervous system disorders 10002026 Amyotrophic lateral sclerosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 17 19:15:00 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA